I applaud CellNetix and PAML for partnering to from a strong regional partnership for molecular testing.
They might not know it yet, but Foundation Medicine in Cambridge, MA is about to eat their lunch (and everyone else's lunch). The big national ASCO meeting for 2013 just occured. Oncologists nationwide are jumping on the FoundationOne molecular test -- amazing clinical application of next generation DNA sequencing with unprecedented depth. The Foundation One test has emerged as the dominant cancer molecular test.
All oncologists at Swedish hospital, Providence health system (including Sacred Heart in Spokane and Olympia hospital), are going to be sending solid tumor samples to Foundation medicine in Cambridge for analysis.
Molecular labs at CellNetix/PAML will be sitting idle as this Harvard/MIT biotech startup has rendered local oncology molecular testing essentially obsolete.